ClinicalTrials.gg
CompletedNCT07222384Updated Aug 7, 2026

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

A Phase 3 interventional study of BNT162b2 (2025/2026 formulation) in COVID-19 and SARS-COV-2 Infection, sponsored by BioNTech SE. Completed at 29 sites in 2 countries. Open to participants aged 5 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Not applicable
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
33rd of 54
344 · median 575
Started
2025
with 3 others
Phase 3
18 of 54
1 open now
Registered
51st of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 33rd largest by enrollment, is one of 4 that started in 2025, is one of 18 in phase 3, and was the 51st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation).

This study is seeking participants 5 through 11 years of age who:

  • have at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19,
  • and are medically stable.

All participants in this study will receive 1 vaccine dose given in the muscle of their arm of a BNT162b2 (2025/2026 formulation) vaccine which targets the COVID-19 virus, specifically the strain selected for the 2025-2026 COVID-19 viral respiratory season.

Participants will take part in this study for about 6 months and will need to visit the clinical study site at least 2 times.

03

Conditions studied

  • COVID-19
  • SARS-COV-2 Infection

Keywords

  • Respiratory Tract Infections
  • Infections
  • Virus Diseases
  • Coronavirus Infections
  • Coronaviridae Infections
  • Lung Diseases
  • Respiratory Tract Diseases
  • COVID-19
  • mRNA Vaccines
  • Nucleic Acid-Based Vaccines
  • Vaccines
  • Biological Products
  • COVID-19 Vaccines
  • Viral Vaccines
  • Antigens
  • Biological Factors
  • BNT162 Vaccine
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Children 5 through 11 years of age at their first appointment.
  • Children with at least 1 underlying stable medical condition that increases their risk of severe COVID-19, as listed in the protocol.

Key Exclusion Criteria:

  • Children who have had confirmed COVID-19 within the last 5 months (150 days).
  • Children who have received a COVID-19 vaccine, either as part of a research study or an approved vaccine, within the last 5 months (150 days).
  • Children who have received a 2025-2026 seasonal COVID-19 vaccination.
  • Children with a history of myocarditis or pericarditis.
  • Children with a previous or current diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C)
  • Children with a medical condition wherein they would be considered for a second dose of COVID-19 vaccine to protect against risk of severe COVID-19 based on standard of care.

Refer to the study contact for further eligibility details.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
344 participants (actual)

Study arms

  • Experimental
    5-11 Years (Higher-Risk Individuals)

    BNT162b2 (2025/2026 formulation)

    Biological: BNT162b2 (2025/2026 formulation)

Interventions

  • BiologicalBNT162b2 (2025/2026 formulation)

    Drug page: BNT162 Vaccine

    BNT162b2 (formulation targeting the 2025/2026 recommended SARS-CoV-2 strain)

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local reactions

    Time frame: For up to 7 days after vaccination

  2. Percentage of participants reporting systemic events

    Time frame: For up to 7 days after vaccination

  3. Percentage of participants reporting adverse events

    Time frame: Through 1 month after vaccination

  4. Percentage of participants reporting serious adverse events

    Time frame: Through 6 months after vaccination

  5. Geometric Mean Fold Rises (GMFRs)

    Time frame: From before vaccination to 1 month after vaccination

07

Study locations

29 sites
  • Stanford University Medical Center CTRU - 800 Welch Road
    Palo Alto, California 94304, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • C & R Research USA
    Homestead, Florida 33030, United States
  • Florida Pharmaceutical Research and Associates
    Miami, Florida 33143, United States
  • Bio-Medical Research LLC
    Miami, Florida 33144, United States
  • Indago Research & Health Center, Inc
    Miami Lakes, Florida 33016, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • GCP Research, Global Clinical professionals
    St. Petersburg, Florida 33714, United States
  • Medical Research Partners
    Ammon, Idaho 83406, United States
  • AMR Clinical
    Oak Brook, Illinois 60523, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Michigan Center of Medical Research (MICHMER)
    Bingham Farms, Michigan 48025, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Cincinnati Children's Hospital Medical Center- Infectious Disease
    Cincinnati, Ohio 45206, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • DM Clinical Research- Cyfair
    Houston, Texas 77065, United States
  • ACRC Trials
    Plano, Texas 75024, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Javara - Privia Medical Group North Texas - Stephenville
    Stephenville, Texas 76401, United States
  • AMR Clinical
    Layton, Utah 84041, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
  • Tekton Research, LLC.
    Richmond, Virginia 23233, United States
  • Clinical Research Puerto Rico
    Guayama, Puerto RICO 00784, Puerto Rico
  • Ponce Medical School Foundation Inc.
    Ponce, Puerto RICO 00716, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jul 2026, 8 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 29, 2025
StartActual
Oct 30, 2025
Primary completionActual
Jul 24, 2026
CompletionActual
Jul 24, 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222384
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Oct 30, 2025
Primary completion
Jul 24, 2026
Completion
Jul 24, 2026
Last update
Aug 7, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion